DNA Group TR Ltd
TASE:DNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
DNA Group TR Ltd
Net Income
DNA Group TR Ltd
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
DNA Group TR Ltd
TASE:DNA
|
Net Income
₪516k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Elsight Ltd
ASX:ELS
|
Net Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mobileye Global Inc
NASDAQ:MBLY
|
Net Income
-$4.1B
|
CAGR 3-Years
-194%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Nayax Ltd
TASE:NYAX
|
Net Income
$35.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Next Vision Stabilized Systems Ltd
TASE:NXSN
|
Net Income
$103.7m
|
CAGR 3-Years
110%
|
CAGR 5-Years
117%
|
CAGR 10-Years
N/A
|
|
|
A
|
Arad Ltd
TASE:ARD
|
Net Income
$29.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
14%
|
CAGR 10-Years
6%
|
|
DNA Group TR Ltd
Glance View
DNA Group (T.R.)Ltd. engages in biotechnology. The firm's areas of activity include: the evaluation of bone density by measuring the velocity of the propagation of sound waves across the bone, using Bimmed, as well as the development of oral delivery of drugs, through its subsidiary, Entera Bio Ltd. Entera Bio Ltd focuses on the development of oral delivery of large molecules to address unmet medical needs. Entera Bio Ltd holds a patent, combining the following technologies: a synthetic molecule absorption enhancer, facilitating the absorption of large molecules and a proprietary formulation to prevent molecule degradation. Entera Bio Ltd’s proprietary oral delivery platform can be applied to a range of large molecules and biologicals. Entera Bio Ltd’s drugs are designated for the following medical conditions: Hypoparathyroidism and Osteoporosis.
See Also
What is DNA Group TR Ltd's Net Income?
Net Income
516k
ILS
Based on the financial report for Jun 30, 2025, DNA Group TR Ltd's Net Income amounts to 516k ILS.
What is DNA Group TR Ltd's Net Income growth rate?
Net Income CAGR 1Y
-97%
Over the last year, the Net Income growth was -97%.
